Document text
Principal Investigator: Weiping Qin
Organization: BRONX VETERANS MEDICAL RESEARCH FDN
Fiscal Year: 2020
Award: $359,365
Funding agency: National Institute of Neurological Disorders and Stroke
Spinal cord injury (SCI) is a serious medical problem that causes loss of sensory, motor and autonomic
function due to the damage of central nerve cells. There are no fully restorative therapies for SCI so far, but
there is one FDA approved agent methylprednisolone (MP) that is being used clinically for the improvement of
function after acute injury because of their high lipid peroxidation inhibition and anti-inflammatory potency.
However, the use of this drug remains controversial as the modest protective functions on nerve cells are
overshadowed by the unfavorable side effects to the rest of the body.
To increase efficacy and reduce their side effects, we have designed and synthesized a nanoparticles-
conjugated MP (Nano-MP), which is composed of MP and a carrier (N2-hydroxypropyl methacrylamide). Our
exciting preliminary data demonstrated that the Nano-MP, by a single administration, is able to be preferentially
delivered to the site of the injured spinal cord in a rodent model of SCI, where the drug is sequestered and
retained mainly by infiltrating inflammatory cells (extrapolated from the action of the parent MP molecule) for
several days. Compared to conventional intravenous delivery of the MP molecule, the single dose of the Nano-
MP administration significantly inhibited oxidative stress in the injured spinal cord. Additionally, we established
a similar nanoparticle delivery of dexamethasone as an anti-inflammatory agent with increased efficacy and
reduced side effects in adjuvant-induced arthritis and lupus nephritis.
Based on this evidence, we hypothesize that the targeted MP delivery to the injury site has similar or
superior therapeutic efficacy (e.g., because of greater delivery efficiency, this approach will be associated with
reduced lipid peroxidation, inflammation and neural damage) in the treatment of acute SCI while reducing side
effects (e.g., those adversely affecting muscle, bone), compared to conventional intravenous delivery of the
parent MP molecule. In this R21 project, we propose to a series of preclinical experiments to test our
hypotheses. We will first determine the potential therapeutic efficacy of Nano-MP on lipid peroxidation,
oxidative stress, inflammation, neural damage and wound-healing after acute SCI (Aim 1). We will further
evaluate if Nano-MP administration, compared to that of free MP, results in a reduction in adverse effects on
skeletal muscle and bone after acute SCI (Aim 2).
The successful completion of the projects of this kind is expected to provide an evidence-based rationale to
further evaluate the effects of Nano-MP on functional recovery after acute SCI, and to strongly support early
clinical studies to test the efficacy of this innovative treatment. If it proven to efficacious in further studies,
administration of nanotechnology-enabled MP holds the potential to be a practical and truly exciting major
advance to preserve function in individuals after acute SCI. The completion of this line of research will lead to a
safe, convenient, effective, and affordable targeted-therapy to provide neuroprotection and to improve
functional recovery for persons with acute SCI.
Terms: <6-Methylprednisolone><6Alpha-Methylprednisolone><Acute><Address><Adjuvant Arthritis><Adjuvant-Induced Arthritis><Adverse effects><Affect><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antiinflammatories><Antiinflammatory Agents><Apoptotic><Blood><Blood Reticuloendothelial System><Body Tissues><Bone Density><Bone Mineral Density><Caring><Cell Body><Cells><Clinical><Clinical Investigator><Clinical Management><Clinical Research><Clinical Study><Collaborations><Common Rat Strains><Complex><Data><Deterioration><Development><Dexamethasone><Direct Costs><Dose><Drug usage><Drugs><Event><FDA approved><Facilities and Administrative Costs><Female><GI bleeding><GI hemorrhage><Gastrointestinal Hemorrhage><Health Care Costs><Health Costs><Healthcare Costs><Hemorrhagic Diathesis><Hemorrhagic Disorders><Impairment><Indirect Costs><Individual><Infection><Inflammation><Inflammatory Infiltrate><Injury><Intervention><Intervention Strategies><Intravenous><Lead><Legal patent><Lesion><Life><Lipid Peroxidation><Lupus Glomerulonephritis><Lupus Nephritis><Medical><Medical center><Medication><Medicine><Medulla Spinalis><Methyl prednisolone><Methylprednisolone><Methylprednisolonum><Metipred><Modeling><Motor><Muscle><Muscle Atrophy><Muscle Disease><Muscle Disorders><Muscle Tissue><Muscular Atrophy><Muscular Diseases><Myopathic Conditions><Myopathic Diseases and Syndromes><Myopathic disease or syndrome><Myopathy><Nanotechnology><Nebraska><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurologic><Neurologic Deficit><Neurological><Neurons><Neuropathy><Neurosciences><Operative Procedures><Operative Surgical Procedures><Oxidative Stress><Parents><Patents><Patients><Pb element><Persons><Pharmaceutic Preparations><Pharmaceutical Preparations><Procedures><Protocol><Protocols documentation><Public Health><Rat><Rats Mammals><Rattus><Recovery of Function><Research><Rest><Risk><Rodent Model><Route><Seasons><Sensory><Series><Severities><Site><Skeletal Muscle><Skeletal bone><Spinal Cord><Spinal Cord Contusions><Spinal Cord Trauma><Spinal Trauma><Spinal cord injured><Spinal cord injury><Steroid Compound><Steroids><Structure><Surgical><Surgical Interventions><Surgical Procedure><Tail><Testing><Time><Tissues><Traumatic Myelopathy><Treatment Efficacy><United States><Universities><Veins><Voluntary Muscle><Wound Repair><antiinflammatory><base><bone><bone loss><carbohydrate metabolism><design><designing><developmental><disability><dosage><drug use><drug/agent><efficacy testing><evidence base><experience><experiment><experimental research><experimental study><function improvement><functional improvement><functional recovery><gastrointestinal bleeding><heavy metal Pb><heavy metal lead><improved><improved functioning><injuries><innovate><innovation><innovative><interest><intervention design><intervention efficacy><interventional strategy><intravenous administration><male><methacrylamide><multidisciplinary><muscle breakdown><muscle bulk><muscle degradation><muscle deterioration><muscle form><muscle loss><muscle mass><muscle wasting><muscular><muscular disorder><nano><nano materials><nano medicinal><nano medicine><nano particle><nano particle delivery><nano tech><nano technology><nano therapeutic><nano-sized particle><nano-technological><nanomaterials><nanomedicinal><nanomedicine><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><nanotech><nanotechnological><nanotherapeutic><neural><neuronal><neuropathic><neuroprotection><new drug class><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel drug class><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pre-clinical><preclinical><preservation><prevent><preventing><relating to nervous system><side effect><site targeted delivery><skeletal><socio-economic><socio-economically><socioeconomically><socioeconomics><surgery><targeted delivery><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic effectiveness><therapeutic efficacy><therapeutically effective><therapy design><therapy efficacy><translational investigator><translational researcher><translational scientist><treatment design><wound healing><wound resolution>